Literature DB >> 26187928

MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer.

Ri Cui1, Wei Meng2, Hui-Lung Sun3, Taewan Kim3, Zhenqing Ye4, Matteo Fassan5, Young-Jun Jeon3, Bin Li2, Caterina Vicentini5, Yong Peng3, Tae Jin Lee3, Zhenghua Luo3, Lan Liu6, Dongyuan Xu6, Esmerina Tili7, Victor Jin4, Justin Middleton3, Arnab Chakravarti2, Tim Lautenschlaeger8, Carlo M Croce9.   

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. Despite advancements and improvements in surgical and medical treatments, the survival rate of lung cancer patients remains frustratingly poor. Local control for early-stage nonsmall cell lung cancer (NSCLC) has dramatically improved over the last decades for both operable and inoperable patients. However, the molecular mechanisms of NSCLC invasion leading to regional and distant disease spread remain poorly understood. Here, we identify microRNA-224 (miR-224) to be significantly up-regulated in NSCLC tissues, particularly in resected NSCLC metastasis. Increased miR-224 expression promotes cell migration, invasion, and proliferation by directly targeting the tumor suppressors TNFα-induced protein 1 (TNFAIP1) and SMAD4. In concordance with in vitro studies, mouse xenograft studies validated that miR-224 functions as a potent oncogenic miRNA in NSCLC in vivo. Moreover, we found promoter hypomethylation and activated ERK signaling to be involved in the regulation of miR-224 expression in NSCLC. Up-regulated miR-224, thus, facilitates tumor progression by shifting the equilibrium of the partially antagonist functions of SMAD4 and TNFAIP1 toward enhanced invasion and growth in NSCLC. Our findings indicate that targeting miR-224 could be effective in the treatment of certain lung cancer patients.

Entities:  

Keywords:  NSCLC; SMAD4; TNFAIP1; metastasis; microRNA

Mesh:

Substances:

Year:  2015        PMID: 26187928      PMCID: PMC4534291          DOI: 10.1073/pnas.1502068112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

3.  Cloning of two rat PDIP1 related genes and their interactions with proliferating cell nuclear antigen.

Authors:  Jianlin Zhou; Xiaoxiao Hu; Xiwen Xiong; Xin Liu; Yunhai Liu; Kaiqun Ren; Tieshan Jiang; Xiang Hu; Jian Zhang
Journal:  J Exp Zool A Comp Exp Biol       Date:  2005-03-01

4.  Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways.

Authors:  G Lagna; A Hata; A Hemmati-Brivanlou; J Massagué
Journal:  Nature       Date:  1996-10-31       Impact factor: 49.962

5.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

Review 6.  Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications.

Authors:  Alexander Chi; Zhongxing Liao; Nam P Nguyen; Jiahong Xu; Baldassarre Stea; Ritsuko Komaki
Journal:  Radiother Oncol       Date:  2010-01-13       Impact factor: 6.280

7.  Restoration of TGF-beta signalling reduces tumorigenicity in human lung cancer cells.

Authors:  G Anumanthan; S K Halder; H Osada; T Takahashi; P P Massion; D P Carbone; P K Datta
Journal:  Br J Cancer       Date:  2005-11-14       Impact factor: 7.640

8.  A comprehensive survey of Ras mutations in cancer.

Authors:  Ian A Prior; Paul D Lewis; Carla Mattos
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

9.  Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer.

Authors:  Hiroshi Hirata; Koji Ueno; Varahram Shahryari; Yuichiro Tanaka; Z Laura Tabatabai; Yuji Hinoda; Rajvir Dahiya
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression.

Authors:  Lin Liu; Jing Nie; Lin Chen; Guanglong Dong; Xiaohui Du; Xin Wu; Yun Tang; Weidong Han
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

View more
  59 in total

Review 1.  A potential role for estrogen in cigarette smoke-induced microRNA alterations and lung cancer.

Authors:  Amit Cohen; Mario Alberto Burgos-Aceves; Yoav Smith
Journal:  Transl Lung Cancer Res       Date:  2016-06

2.  Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development.

Authors:  Nina J Chu; Robert A Anders; Elana J Fertig; Minwei Cao; Alexander C Hopkins; Bridget P Keenan; Aleksandra Popovic; Todd D Armstrong; Elizabeth M Jaffee; Jacquelyn W Zimmerman
Journal:  Cancer Prev Res (Phila)       Date:  2020-05-14

Review 3.  Mutual regulation of microRNAs and DNA methylation in human cancers.

Authors:  Sumei Wang; Wanyin Wu; Francois X Claret
Journal:  Epigenetics       Date:  2017-01-06       Impact factor: 4.528

4.  MiR-590 suppresses the progression of non-small cell lung cancer by regulating YAP1 and Wnt/β-catenin signaling.

Authors:  X Hao; A Su
Journal:  Clin Transl Oncol       Date:  2022-01-15       Impact factor: 3.405

5.  Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.

Authors:  Andrea E Calvert; Alexandra Chalastanis; Yongfei Wu; Lisa A Hurley; Fotini M Kouri; Yingtao Bi; Maureen Kachman; Jasmine L May; Elizabeth Bartom; Youjia Hua; Rama K Mishra; Gary E Schiltz; Oleksii Dubrovskyi; Andrew P Mazar; Marcus E Peter; Hongwu Zheng; C David James; Charles F Burant; Navdeep S Chandel; Ramana V Davuluri; Craig Horbinski; Alexander H Stegh
Journal:  Cell Rep       Date:  2017-05-30       Impact factor: 9.423

6.  Predictive relevance of miR-34a, miR-224 and miR-342 in patients with advanced squamous cell carcinoma of the lung undergoing palliative chemotherapy.

Authors:  Vlastimil Kulda; Martin Svaton; Petr Mukensnabl; Kristyna Hrda; Pavel Dvorak; Zbynek Houdek; Katerina Houfkova; Radana Vrzakova; Vaclav Babuska; Milos Pesek; Martin Pesta
Journal:  Oncol Lett       Date:  2017-11-02       Impact factor: 2.967

7.  miR-132 inhibits lung cancer cell migration and invasion by targeting SOX4.

Authors:  Yang Li; Lingling Zu; Yuli Wang; Min Wang; Peirui Chen; Qinghua Zhou
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

8.  MiR-195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA.

Authors:  Min Wang; Junjie Zhang; Linlong Tong; Xiaofei Ma; Xinguang Qiu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 9.  Roles of exosomes in diagnosis and treatment of colorectal cancer.

Authors:  Yvette Umwali; Cong-Bo Yue; Abakundana Nsenga Ariston Gabriel; Yi Zhang; Xin Zhang
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

Review 10.  Comprehensive understanding of anchorage-independent survival and its implication in cancer metastasis.

Authors:  Zhong Deng; Huixue Wang; Jinlong Liu; Yuan Deng; Nu Zhang
Journal:  Cell Death Dis       Date:  2021-06-18       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.